Martin Filipits - Concepedia

Author

Martin Filipits

Also Known As

F Fitzal, Filipits, M., Kollmeier, Jens, M Filipits, M Gnant, M. Filipits, M. Filipits2, MARTIN FILIPITS, Martin Filipits, Theodora Psaltopoulou

378

Publications

12.8K

Citations

H-Index

Concepts

All Affiliations

Medical University of Vienna Comprehensive Cancer Center Vienna Medical University of Graz Paracelsus Medical University Austrian Breast & Colorectal Cancer Study Group

About

Martin Filipits is an author at Medical University of Vienna specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	32	56	3.3K
2	Health Sciences	10	10	533
3	Public Health	3	3	157
4	Engineering	2	2	110
5	Natural Sciences	2	2	155

Martin Filipits

132

Publications

11.3K

Citations

H-Index

Page 1

	Year	Citations
DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy Ken A. Olaussen, Ariane Dunant, Pierre Fouret, New England Journal of Medicine	2006	1.7K
A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors Martin Filipits, Margaretha Rudas, R. Jakesz, Clinical Cancer Research	2011	703
Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma Anna S. Berghoff, Barbara Kiesel, Georg Widhalm, Neuro-Oncology	2014	573
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone Michael Gnant, Martin Filipits, Richard Greil, Annals of Oncology Surgical OncologyBreast OncologyRecurrence ScoreDistant RecurrenceCancer Recurrence	2013	392
ERCC1 Isoform Expression and DNA Repair in Non–Small-Cell Lung Cancer Luc Friboulet, Ken A. Olaussen, Jean‐Pierre Pignon, New England Journal of Medicine	2013	362
Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non–Small-Cell Lung Cancer Élisabeth Brambilla, Gwénaël Le Teuff, Sophie Marguet, Journal of Clinical Oncology	2016	354
Pooled Analysis of the Prognostic and Predictive Effects of <i>KRAS</i> Mutation Status and <i>KRAS</i> Mutation Subtype in Early-Stage Resected Non–Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy Frances A. Shepherd, Caroline Domerg, Pierre Hainaut, Journal of Clinical Oncology	2013	288
Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop Robert Pirker, Felix Herth, Keith M. Kerr, Journal of Thoracic Oncology Egfr Mutation TestingEuropean WorkshopMedicinePathologyCancer Genomics	2010	281
<i>EGFR/KRAS/BRAF</i> Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node Metastases Katharina Schmid, Natalie Oehl, Fritz Wrba, Clinical Cancer Research	2009	262
Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50 Risk of Recurrence Score Ivana Šestak, Jack Cuzick, Mitch Dowsett, Journal of Clinical Oncology	2014	242

Page 1